Abstract Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.</p
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Philip G Janicak1, Elizabeth A Winans2,31Department of Psychiatry, Rush University Medical Center, C...
An amendment to this paper has been published and can be accessed via the original article
Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceut...
Abstract Background Patients having chronic schizophr...
Purpose: Cardiovascular and metabolic adverse events are costly to treat, and their incidence is inc...
Maximilian Gahr1,*, Markus A K&ouml;lle1,*, Carlos Sch&ouml;nfeldt-Lecuona1, Peter Lepping2,...
To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting inje...
There was an error in the relapse rate reduction reported in Figure 2 in this article by Zaniolo et ...
AbstractObjectiveThis study updated a 2001 decision economic model that used indirect data and confi...
Objective: Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are kno...
In the last decade, the U. S. Food and Drug Administration has approved a series of second-generatio...
Background: The development of paliperidone extended release (ER) may represent a new strategy to im...
Objective : This study aimed to evaluate the clinical efficacy, safety, and tolerability of paliperi...
Objective: To model the cost effectiveness of paliperidone palmitate (paliperidone long-Acting injec...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Philip G Janicak1, Elizabeth A Winans2,31Department of Psychiatry, Rush University Medical Center, C...
An amendment to this paper has been published and can be accessed via the original article
Background: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceut...
Abstract Background Patients having chronic schizophr...
Purpose: Cardiovascular and metabolic adverse events are costly to treat, and their incidence is inc...
Maximilian Gahr1,*, Markus A K&ouml;lle1,*, Carlos Sch&ouml;nfeldt-Lecuona1, Peter Lepping2,...
To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting inje...
There was an error in the relapse rate reduction reported in Figure 2 in this article by Zaniolo et ...
AbstractObjectiveThis study updated a 2001 decision economic model that used indirect data and confi...
Objective: Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are kno...
In the last decade, the U. S. Food and Drug Administration has approved a series of second-generatio...
Background: The development of paliperidone extended release (ER) may represent a new strategy to im...
Objective : This study aimed to evaluate the clinical efficacy, safety, and tolerability of paliperi...
Objective: To model the cost effectiveness of paliperidone palmitate (paliperidone long-Acting injec...
Background: Schizophrenia is a severe form of mental illness which is associated with significant an...
Philip G Janicak1, Elizabeth A Winans2,31Department of Psychiatry, Rush University Medical Center, C...
An amendment to this paper has been published and can be accessed via the original article